Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)

Atrial FibrillationMyocardial InfarctionThrombosis and Stroke

Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry

J Am Coll Cardiol.

Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP; ORBIT-AF Investigators and Patients

doi: 10.1016/j.jacc.2016.09.966.

Atrial Fibrillation

Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Am Heart J.

Jackson LR 2nd, Kim S, Blanco R, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Kowey PR, Mahaffey KW, Hylek EM, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II.

doi: 10.1016/j.ahj.2020.04.016.

Atrial Fibrillation

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

BMJ.

Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB

doi: 10.1136/bmj.j510.

Atrial Fibrillation

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

Eur Heart J.

Wang KL, Lopes RD, Patel MR, Büller HR, Tan DS, Chiang CE, Giugliano RP

doi: 10.1093/eurheartj/

Atrial FibrillationHeart, Artery and Coronary Diseases

The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials

Circulation.

Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, Brueckmann M, Kleine E, Ten Berg JM

doi: 10.1161/CIRCULATIONAHA.

Atrial FibrillationThrombosis and Stroke

Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review

JAMA Cardiol.

Eikelboom JW, Quinlan DJ, Hirsh J, Connolly SJ, Weitz JI

doi: 10.1001/jamacardio.

Atrial FibrillationHeart, Artery and Coronary DiseasesMyocardial Infarction

Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study

JAMA Cardiol.

Inohara T, Shrader P, Pieper K, Blanco RG, Thomas L, Singer DE, Freeman JV, Allen LA, Fonarow GC, Gersh B, Ezekowitz MD, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Steinberg BA, Peterson ED, Piccini JP

doi: 10.1001/jamacardio.

Atrial Fibrillation

Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

Circ Arrhythm Electrophysiol.

Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, Freeman JV, Fonarow GC, Gersh BJ, Hylek EM, Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED, Piccini JP

doi: 10.1161/CIRCEP.119.007775.

Atrial Fibrillation

Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis

J Am Heart Assoc

Sitticharoenchai P, Takkavatakarn K, Boonyaratavej S, Praditpornsilpa K, Eiam-Ong S, Susantitaphong P

doi: 10.1161/JAHA.120.019609

Related content

Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry

Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)

Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.

Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials

The Efficacy and Safety of the Use of Non-Vitamin-K Antagonist Oral Anticoagulants in Patients with Non-Valvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials

Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review

Association of Atrial Fibrillation Clinical Phenotypes with Treatment Patterns and Outcomes: A Multicenter Registry Study

Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

Non-Vitamin K Antagonist Oral Anticoagulants Provide Less Adverse Renal Outcomes Than Warfarin In Non-Valvular Atrial Fibrillation: A Systematic Review and MetaAnalysis